市場調査報告書：幹細胞治療と再生医療

INTRODUCTION
SUMMARY
- Summary Table: GLOBAL FORECAST OF REVENUES FOR STEM CELL AND CYTOKINE THERAPIES IN REGENERATIVE MEDICINE, THROUGH 2010 ($ BILLIONS)
- Summary Figure: GLOBAL FORECAST OF REVENUES FOR STEM CELL AND CYTOKINE THERAPIES IN REGENERATIVE MEDICINE, 2003-2010 ($ BILLIONS)
OVERVIEW
- Table 1 PERCENT OF PERSONS USING PRESCRIPTION DRUGS IN THE PAST MONTH IN THE U.S., 1999-2000
  - GROWTH FACTORS AND CYTOKINES
- Table 2 SELECTED CYTOKINES OR GROWTH FACTORS RELEVANT TO REGENERATIVE MEDICINE
- Table 2 (CONTINUED)
  - STEM AND PROGENITOR CELLS
  - WORLDWIDE MARKETS FOR REGENERATIVE MEDICINE
- Table 3 LEADING CAUSES OF DEATH IN THE U.S., 2001
- Table 4 PREVALENCE OF MEDICAL CONDITIONS IN THE U.S. WITH POTENTIAL CELL THERAPIES
- Table 5 AGING OF THE U.S. POPULATION
- Table 6 POPULATION OF COUNTRIES OF THE EUROPEAN UNION, 2003
- Table 7 DESCENDANTS OF THE HUMAN MESENCHYMAL STEM CELL
- Table 8 A PARTIAL LIST OF DISEASES TREATED USING CORD BLOOD STEM CELLS
- Table 9 DERIVATION OF BODY TISSUE TYPES FROM GERM LAYERS
- Table 10 CELL TYPES DERIVED FROM EMBRYONIC STEM CELLS IN VITRO
- Table 10 (CONTINUED)
- Table 11 MARKERS OF PLURIPOTENT CELLS IN MOUSE, MAN, AND MONKEY
- Table 12 EMBRYONIC STEM CELL LINES THAT MEET NIH FUNDING REQUIREMENTS, WHICH ARE AVAILABLE FOR SHIPPING
  - CELL-BASED GENE THERAPY
  - U.S. REGULATION
    - DEVICES
- Table 13 FOOD AND DRUG ADMINISTRATION BODIES INVOLVED IN IMPLANT REGULATION
  - INTERNATIONAL ISSUES
  - OFFSHORE CELL-THERAPY TREATMENTS
    - OFFSHORE CELL-THERAPY TREATMENTS (CONTINUED)
APPLICATIONS FOR PROGENITOR CELL THERAPIES
- Figure 1 HEMATOPOIESIS
- Table 14 A PARTIAL LIST OF DISEASES TREATED WITH HEMATOPOIETIC STEM CELLS
- Table 14 (CONTINUED)
- Table 15 COMMERCIAL OPPORTUNITIES FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
- Table 16 APPROVED BIOPHARMACEUTICALS FOR THE REGENERATION OF BLOOD AND IMMUNE CELLS AFTER CHEMOTHERAPY
- Table 17 SALES OF THERAPEUTIC REGENERATIVE CYTOKINES FOR BLOOD AND IMMUNE DISEASES, THROUGH 2010 ($ MILLIONS)
- Figure 2 SALES OF THERAPEUTIC REGENERATIVE CYTOKINES FOR BLOOD AND IMMUNE DISEASES, 2003-2010 ($ MILLIONS)
- Table 18 COMMERCIAL UMBILICAL CORD BLOOD STORAGE COMPANIES
- Table 19 FEES CHARGED BY MAJOR UMBILICAL CORD BLOOD BANKS, 2005 ($)
- Table 20 WORLDWIDE REVENUES FROM CORD BLOOD HARVEST AND STORAGE, THROUGH 2010 ($ MILLIONS)
- Figure 3 WORLDWIDE REVENUES FROM CORD BLOOD HARVEST AND STORAGE, 2003-2010 ($ MILLIONS)
- Table 21 WORLDWIDE REVENUES FROM EXPANSION AND CULTURE OF THERAPEUTIC STEM CELLS, THROUGH 2010 ($ MILLIONS)
- Figure 4 WORLDWIDE REVENUES FROM EXPANSION AND CULTURE OF THERAPEUTIC STEM CELLS, 2003-2010 ($ MILLIONS)
- Table 22 AQUIRED IMMONDEFICIENCY CASES REPORTED BY YEAR IN THE U.S., 1985-2003
- Table 23 SIZE OF THE AIDS/HIV EPIDEMIC
- Table 24 GLOBAL FORECAST OF REVENUES FOR BLOOD AND IMMUNE DISEASES ($ MILLIONS)
- Table 5 GLOBAL FORECAST OF REVENUES FOR BLOOD AND IMMUNE DISEASES ($ MILLIONS)
  - SKIN
    - SKIN CELL PROGENITORS
    - BURNS
    - ULCERS
      - ULCERS (CONTINUED)
    - MARKET OPPORTUNITIES FOR SKIN CELL THERAPIES
      - MARKET OPPORTUNITIES FOR SKIN CELL THERAPIES (CONTINUED)
- Table 25 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE WOUND THERAPY PRODUCTS, THROUGH 2010 ($ MILLIONS)
- Figure 6 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE WOUND THERAPY PRODUCTS, 2003-2010 ($ MILLIONS)
  - BONE
    - BONE FRACTURES
      - Bone Metabolism
      - Current Therapies
      - Cell Therapies for Bone Fractures
      - Growth Factors and Morphogenic Proteins
- Table 26 GROWTH FACTOR PRODUCTS FOR BONE HEALING
- Table 27 GROWTH FACTORS DEVELOPED BUT NOT YET APPROVED FOR BONE INDICATIONS
- Table 28 SPINAL FUSION DATA, U.S. 1998-2002 ($)
- Table 29 NUMBER OF LOWER LEG FRACTURE, 1998-2002
- Table 30 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE THERAPIES FOR SPINAL FUSIONS AND BONE FRACTURES ($ MILLIONS)
- Figure 7 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE THERAPIES FOR SPINAL FUSIONS AND BONE FRACTURES ($ MILLIONS)
  - CARTILAGE
- Table 31 PRODUCTS FOR REGENERATIVE CARTILAGE REPAIR
- Table 32 GLOBAL FORECAST OF SALES OF CELL THERAPY PRODUCTS TO REPAIR CARTILAGE, THROUGH 2010 ($ MILLIONS)
- Figure 8 GLOBAL FORECAST OF SALES OF CELL THERAPY PRODUCTS TO REPAIR CARTILAGE, 2003-2010 ($ MILLIONS)
  - CARDIOVASCULAR SYSTEM
    - CONGESTIVE HEART FAILURE
      - Current Therapies
    - CORONARY HEART DISEASE
      - Current Therapies
    - CELL THERAPIES FOR CHF OR CORONARY DISEASE
      - Cell Therapies for CHF or Coronary Disease (Continued)
      - Cell Therapies for CHF or Coronary Disease (Continued)
    - CARDIAC ARRYTHMIA
      - Current Therapy
      - Cell Therapies
    - MARKET OPPORTUNITIES FOR CARDIOVASCULAR CELL THERAPIES
- Table 33 PREVALENCE OF HEART DISEASE IN U.S. ADULTS (18 YEARS AND OVER), 2002 (THOUSAND)
  - TEETH
  - HAIR
  - BRAIN AND NERVOUS SYSTEM
    - NEURAL STEM CELLS
    - LYSOSOMAL STORAGE DISEASES
    - DISORDERS OF THE MYELIN SHEATH
    - SPINAL CORD INJURY
      - Spinal Cord Injury (Continued)
    - STROKE
- Table 34 DEATH RATES PER 100,000 FROM CEREBROVASCULAR DISEASE (STROKE) IN THE U.S., 1960 AND 2002
  - EYES
    - EYES (CONTINUED)
      - Market Opportunities
  - LIVER
    - HUMAN CELL THERAPIES
      - Human Cell Therapies (Continued)
      - Markets for Regenerative Therapies for the Liver
  - KIDNEY
  - DIABETES
- Table 35 GLOBAL PREVALENCE OF DIABETES IN EUROPE, AGES 20 TO 79 2003 AND 2025 (THOUSANDS)
  - REPRODUCTIVE MEDICINE
    - MARKET OPPORTUNITIES FOR OOCYTE CRYOPRESERVATION
- Table 36 GLOBAL FORECAST OF REVENUES DERIVED FROM OOCYTE STORAGE, THROUGH 2010 ($ MILLION)
- Figure 9 GLOBAL FORECAST OF REVENUES DERIVED FROM OOCYTE STORAGE, 2003-2010 ($ MILLION)
PRODUCTS USED IN CELL THERAPY AND REGENERATIVE MEDICINE
- Table 37 CYTOKINES AND GROWTH FACTORS IN REGENERATIVE MEDICINE
  - LIVING CELL THERAPIES
    - HEMATOPOIETIC AND IMMUNE CELL THERAPIES
- Table 38 LIVING BLOOD AND IMMUNE CELL THERAPEUTIC PRODUCTS IN DEVELOPMENT
- Table 39 LIVING SKIN EQUIVALENTS USED THERAPEUTICALLY
- Table 40 LIVING-CELL PRODUCTS USED THERAPEUTICALLY TO REPAIR CARTILAGE
- Table 41 MUSCLE CELLS USED AS THERAPEUTIC PRODUCTS
  - STEM CELL STORAGE
    - BIOARCHIVE STEM CELL SYSTEM
    - CCEL CELLULAR STORAGE FREEZER
STRUCTURE OF THE INDUSTRY
- Table 42 COMPANIES SUPPLYING APPROVED CYTOKINE OR GROWTH FACTOR THERAPIES
- Table 43 RANKINGS AND MARKET SHARES OF COMPANIES FOR CYTOKINES AND GROWTH FACTORS IN 2004 (REVENUES)
- Table 44 COMPANIES DEVELOPING GROWTH FACTOR OR CYTOKINE PRODUCTS
  - UMBILICAL CORD STEM CELL COMPANIES
- Table 45 2004 WORLDWIDE MARKET RANKINGS FOR UMBILICAL CORD STEM CELL STORAGE COMPANIES
  - CELL THERAPY COMPANIES
- Table 46 FOCUS OF STEM AND PROGENITOR CELL THERAPY COMPANIES
- Table 46 (CONTINUED)
- Table 46 (CONTINUED)
  - PATENTS
    - PATENTS (CONTINUED)
- Table 47 U.S. PATENT APPLICATIONS FROM JANUARY 1, 2001 THROUGH SEPTEMBER 8, 2005, WITH SELECTED STEM CELL SEARCH TERMS
- Table 48 SELECTED U.S. STEM CELL PATENTS ISSUED BETWEEN JANUARY 2002 AND SEPTEMBER 2005
- Table 48 (CONTINUED)
- Table 48 (CONTINUED)
- Table 48 (CONTINUED)
  - ATTRITION
- Table 49 DISAPPEARING NAMES IN REGENERATIVE MEDICINE
COMPANY PROFILES
APPENDIX
LIST OF TABLES
Summary Table:
Table 1 PERCENT OF PERSONS USING PRESCRIPTION DRUGS IN THE PAST MONTH IN THE U.S., 1999-2000
Table 2 SELECTED CYTOKINES OR GROWTH FACTORS RELEVANT TO REGENERATIVE MEDICINE
Table 3 LEADING CAUSES OF DEATH IN THE U.S., 2001
Table 4 PREVALENCE OF MEDICAL CONDITIONS IN THE U.S. WITH POTENTIAL CELL THERAPIES
Table 5 AGING OF THE U.S. POPULATION
Table 6 POPULATION OF COUNTRIES OF THE EUROPEAN UNION, 2003
Table 7 DESCENDANTS OF THE HUMAN MESENCHYMAL STEM CELL
Table 8 A PARTIAL LIST OF DISEASES TREATED USING
CORD BLOOD STEM CELLS
Table 9 DERIVATION OF BODY TISSUE TYPES FROM GERM LAYERS
Table 10 CELL TYPES DERIVED FROM EMBRYONIC STEM CELLS IN VITRO
Table 11 MARKERS OF PLURIPOTENT CELLS IN MOUSE, MAN, AND MONKEY
Table 12 EMBRYONIC STEM CELL LINES THAT MEET NIH FUNDING REQUIREMENTS, WHICH ARE AVAILABLE FOR SHIPPING
Table 13 FOOD AND DRUG ADMINISTRATION BODIES INVOLVED IN IMPLANT REGULATION
Table 14 A PARTIAL LIST OF DISEASES TREATED WITH HEMATOPOIETIC STEM CELLS
Table 15 COMMERCIAL OPPORTUNITIES FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
Table 16 APPROVED BIOPHARMACEUTICALS FOR THE REGENERATION OF BLOOD AND IMMUNE CELLS AFTER CHEMOTHERAPY
Table 17 SALES OF THERAPEUTIC REGENERATIVE CYTOKINES FOR BLOOD AND IMMUNE DISEASES, THROUGH 2010 ($ MILLIONS)
Table 18 COMMERCIAL UMBILICAL CORD BLOOD STORAGE COMPANIES
Table 19 FEES CHARGED BY MAJOR UMBILICAL CORD BLOOD BANKS, 2005 ($)
Table 20 WORLDWIDE REVENUES FROM CORD BLOOD HARVEST AND STORAGE, THROUGH 2010 ($ MILLIONS)
Table 21 WORLDWIDE REVENUES FROM EXPANSION AND CULTURE OF THERAPEUTIC STEM CELLS, THROUGH 2010 ($ MILLIONS)
Table 22 AQUIRED IMMONDEFICIENCY CASES REPORTED BY YEAR IN THE U.S., 1985-2003
Table 23 SIZE OF THE AIDS/HIV EPIDEMIC
Table 24 GLOBAL FORECAST OF REVENUES FOR BLOOD AND IMMUNE DISEASES ($ MILLIONS)
Table 25 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE WOUND THERAPY PRODUCTS, THROUGH 2010 ($ MILLIONS)
Table 26 GROWTH FACTOR PRODUCTS FOR BONE HEALING
Table 27 GROWTH FACTORS DEVELOPED BUT NOT YET APPROVED FOR BONE INDICATIONS
Table 28 SPINAL FUSION DATA, U.S. 1998-2002 ($)
Table 29 NUMBER OF LOWER LEG FRACTURE, 1998-2002
Table 30 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE THERAPIES FOR SPINAL FUSIONS AND BONE FRACTURES ($ MILLIONS)
Table 31 PRODUCTS FOR REGENERATIVE CARTILAGE REPAIR
Table 32 GLOBAL FORECAST OF SALES OF CELL THERAPY PRODUCTS TO REPAIR CARTILAGE, THROUGH 2010 ($ MILLIONS)
Table 33 PREVALENCE OF HEART DISEASE IN U.S. ADULTS (18 YEARS AND OVER), 2002 (THOUSAND)
Table 34 DEATH RATES PER 100,000 FROM CEREBROVASCULAR DISEASE (STROKE) IN THE U.S., 1960 AND 2002
Table 35 GLOBAL PREVALENCE OF DIABETES IN EUROPE, AGES 20 TO 79, 2003 AND 2005 (THOUSANDS)
Table 36 GLOBAL FORECAST OF REVENUES DERIVED FROM OOCYTE STORAGE, THROUGH 2010 ($ MILLION)
Table 37 CYTOKINES AND GROWTH FACTORS IN REGENERATIVE MEDICINE
Table 38 LIVING BLOOD AND IMMUNE CELL THERAPEUTIC PRODUCTS IN DEVELOPMENT
Table 39 LIVING SKIN EQUIVALENTS USED THERAPEUTICALLY
Table 40 LIVING-CELL PRODUCTS USED THERAPEUTICALLY TO REPAIR CARTILAGE
Table 41 MUSCLE CELLS USED AS THERAPEUTIC PRODUCTS
Table 42 COMPANIES SUPPLYING APPROVED CYTOKINE OR GROWTH FACTOR THERAPIES
Table 43 RANKINGS AND MARKET SHARES OF COMPANIES FOR CYTOKINES AND GROWTH FACTORS IN 2004 (REVENUES)
Table 44 COMPANIES DEVELOPING GROWTH FACTOR OR CYTOKINE PRODUCTS
Table 45 2004 WORLDWIDE MARKET RANKINGS FOR UMBILICAL CORD STEM CELL STORAGE COMPANIES
Table 46 FOCUS OF STEM AND PROGENITOR CELL THERAPY COMPANIES
Table 47 U.S. PATENT APPLICATIONS FROM JANUARY 1, 2001 THROUGH SEPTEMBER 8, 2005, WITH SELECTED STEM CELL SEARCH TERMS
Table 48 SELECTED U.S. STEM CELL PATENTS ISSUED BETWEEN JANUARY 2002 AND SEPTEMBER 2005
Table 49 DISAPPEARING NAMES IN REGENERATIVE MEDICINE
LIST OF FIGURES
Summary Figure:
Figure 1 HEMATOPOIESIS
Figure 2 SALES OF THERAPEUTIC REGENERATIVE CYTOKINES FOR BLOOD AND IMMUNE DISEASES, 2003-2010 ($ MILLIONS)
Figure 3 WORLDWIDE REVENUES FROM CORD BLOOD HARVEST AND STORAGE, 2003-2010 ($ MILLIONS)
Figure 4 WORLDWIDE REVENUES FROM EXPANSION AND CULTURE OF THERAPEUTIC STEM CELLS, 2003-2010 ($ MILLIONS)
Table 5 GLOBAL FORECAST OF REVENUES FOR BLOOD AND IMMUNE DISEASES ($ MILLIONS)
Figure 6 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE WOUND THERAPY PRODUCTS, 2003-2010 ($ MILLIONS)
Figure 7 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE THERAPIES FOR SPINAL FUSIONS AND BONE FRACTURES ($ MILLIONS)
Figure 8 GLOBAL FORECAST OF SALES OF CELL THERAPY PRODUCTS TO REPAIR CARTILAGE, 2003-2010 ($ MILLIONS)
Figure 9 GLOBAL FORECAST OF REVENUES DERIVED FROM OOCYTE STORAGE, 2003-2010 ($ MILLION)

幹細胞治療と再生医療：現在のアプリケーションと将来の可能性

Stem Cell Therapies and Regenerative Medicine: Current Applications and Future Possibilities

Table of Contents